Key statistics
Previous close$73.03
Open$73.89
Day high$75.28
Day low$73.60
52-week high$75.28
52-week low$54.70
Market cap123.92B
Volume6.88M
Average volume8.55M
P/E ratio13.47
Forward P/E—
EPS5.51
Dividend yield+5.71%
Market context
Why it moved
Altria Group (MO) shares rose sharply, driven by institutional buying interest highlighted by Bank of New York Mellon's share purchase, while the stock's appeal as a defensive, high-yield holding attracted investors amid broader market uncertainty and a risk-off global environment.
What is happening
Recent company-specific developments and publisher coverage.
July 17, 2026Altria Group rose on Friday, outperforming a broadly defensive market as consumer staples attracted rotation away from tech and AI-related names. The stock closed near its 52-week high of $74.56, supported by a backdrop of steady institutional accumulation — with Bank of New York Mellon, Wealthfront, and D.A. Davidson among firms recently adding to positions — and a ~5.8% dividend yield that appeals in the current risk-off environment. Q1 2026 results beat estimates (EPS $1.32 vs. $1.25 expected, revenue $4.76B vs. $4.58B), and FY 2026 EPS guidance of $5.56–$5.72 remains intact, though analyst consensus stays at Hold with a $70.78 average target — well below current trading levels.1.6158
July 17, 2026Altria Group rallied alongside consumer staples peers as investors rotated out of AI and semiconductor stocks into defensive, high-yield names amid renewed tech sector pressure. The Consumer Staples Select Sector SPDR (XLP) surged ~2.6% — its strongest session since April 2025 — while the broader S&P 500 slipped, benefiting dividend-focused stocks like Altria. Adding to the constructive backdrop, a Yahoo Finance report highlighted Altria's outlook being bolstered by new FDA rule proposals targeting foreign tobacco manufacturers, reinforcing its domestic competitive moat. With a 6.0% dividend yield, Q1 EPS of $1.32 that beat estimates, and its on! nicotine pouch brand growing 18% shipment volume, Altria closed near its 52-week high.3.5593
July 16, 2026Altria Group closed modestly higher, supported by continued institutional accumulation and renewed investor attention as it lands on Zacks' most-searched stocks list. Multiple institutions significantly increased their MO stakes in Q1, while the company's Q1 beat — $1.32 EPS vs. $1.25 expected and $4.76B in revenue vs. $4.58B estimated — alongside raised FY2026 guidance of $5.56–$5.72 EPS keeps fundamentals constructive. A key regulatory wildcard is also in focus: public health groups sued the FDA over its new flavored e-cigarette/nicotine pouch policy, which Altria publicly endorsed as critical to combating the illicit market — an outcome that could shape the company's next-gen product runway heading into its July 30 earnings report.0.5131
July 15, 2026Altria Group declined despite a broadly higher market on a cooler-than-expected CPI report, as the stock pulled back from near its 52-week high of $74.56 amid mixed institutional sentiment and a consensus analyst price target of $70.78 — essentially at current levels. The selloff came as investors appeared to book profits following a strong run (shares up ~25% year-to-date), with some concern that the stock looks modestly overvalued relative to fair-value models, even as Q1 results beat estimates ($1.32 EPS vs. $1.25 expected) and FY2026 guidance was reaffirmed at $5.56–$5.72 EPS. The consumer defensive sector (XLP) also closed lower, underperforming the broader S&P 500, as defensives gave back ground in a risk-on session driven by tech and growth stocks responding to the soft inflation print.-2.3793
July 14, 2026Altria Group closed essentially flat as investors balanced the company's strong fundamental backdrop against a broader market selloff triggered by renewed U.S.-Iran military tensions that sent oil prices surging. Key investor focus centers on the upcoming Q2 2026 earnings report (expected July 30, with analysts projecting $1.50 EPS), while a recent Bank of America note raised estimates and maintained an $82 price target following favorable FDA regulatory developments — including authorization of 20 ZYN variants and relaxed enforcement on nicotine pouches — that helped the tobacco sector outperform most consumer staples sub-groups in Q2. With a 5.9% dividend yield, a 60th dividend increase in 56 years, and MO shares up ~24% over the past year, income-oriented investors continue to view the stock as a defensive holding amid market rotation away from AI/tech.0.1114
July 11, 2026Altria Group closed modestly higher, edging up as investors weighed a broadly positive backdrop for tobacco stocks amid a sector re-rating narrative. A Wall Street Journal report highlighted that tobacco companies pivoting to smoke-free products are "rejoining polite society" with institutional investors returning after years of ESG-driven exclusions — a tailwind that has benefited peers Philip Morris and BAT more directly, given their larger smoke-free revenue mix. For Altria specifically, attention is building ahead of its Q2 2026 earnings on July 30, with analysts expecting EPS of $1.50, up ~4% year-over-year, following a strong Q1 beat. Today also marked the payment date for Altria's $1.06 quarterly dividend (~5.9% annualized yield), reinforcing its appeal as a Dividend King in a market rotating toward income and defensive assets. UBS recently set a $79 price target, though the consensus remains Hold at $70.78.0.2514
July 10, 2026Altria Group declined as geopolitical-driven market volatility and sector-wide headwinds in consumer staples weighed on the stock, with the XLP ETF also finishing lower on the day. Investors are navigating a complex narrative around the company: while Altria's Q1 earnings beat expectations (EPS $1.32 vs. $1.25 est.) and a $1.06 quarterly dividend is set to pay July 10, the broader tobacco story is shifting. Peer Philip Morris gained fresh attention after the FDA granted ZYN nicotine pouches a Modified Risk designation, spotlighting the accelerating industry pivot to smoke-free products — an area where Altria, still heavily cigarette-dependent, faces strategic pressure. UBS recently raised its price target to $79, but analyst sentiment remains mixed with a consensus Hold and $70.78 target.-1.6756
July 9, 2026Altria Group closed essentially flat amid a broader defensive rotation as geopolitical tensions—President Trump declaring the U.S.-Iran ceasefire "over" and sparking an oil price surge—drove investors into consumer staples while tech and cyclicals sold off. UBS raised its price target on Altria to $79 (from $76), maintaining a Buy rating and citing improving EPS growth prospects, favorable FDA guidance on next-generation products like on! pouches, and potential for guidance upgrades. With a $1.06 quarterly dividend due July 10th and a 5.8% yield, Altria's defensive profile and smoke-free product expansion narrative continue to attract income-focused investors even as Marlboro volume pressures persist.-0.2056
Investing.com · July 17, 2026Altria Group stock hits 52-week high at $74.60↗MarketBeat · July 17, 2026Altria Group (NYSE:MO) Reaches New 12-Month High - Here's Why↗Barchart.com · July 16, 2026Altria to Host Webcast of 2026 Second-Quarter and First-Half Results↗Tobacco Reporter · July 16, 2026Altria Schedules Financial Webcast for July 30↗Simply Wall Street · July 14, 2026Altria Group (MO) Looks 2% Overvalued As Investors Weigh Its Smoke Free Shift↗Stocktwits · May 1, 2026MO Stock Eyes Best Week In Six Years: Altria’s Pricing Power Offsets Falling Cigarette Volumes In Q1↗ Benzinga · July 7, 2026UBS Maintains Buy on Altria Group, Raises Price Target to $79Mt Newswire · July 7, 2026UBS Adjusts Price Target on Altria Group to $79 From $76Mt Newswire · June 26, 2026Philip Morris, Other Tobacco Stocks Rise After FDA Proposes Foreign Tobacco RegulationsMt Newswire · May 28, 2026Altria Group Insider Sold Shares Worth $418,318, According to a Recent SEC FilingMt Newswire · May 27, 2026Jefferies Adjusts Price Target on Altria to $60 From $50, Maintains Underperform RatingMt Newswire · May 21, 2026Altria Subsidiary USSTC Plans Facility RelocationBenzinga · May 21, 2026Altria Group's U.S. Smokeless Tobacco Subsidiary To Shift Production Operations From Nashville To New Site In Hopkinsville, Kentucky; Nashville Operations Anticipated To Shut Down Completely In Early 2028Benzinga · May 18, 2026Altria Group Elects Salvatore Mancuso As CEO Effective May 14, 2026
